A Single Dose, Dose Escalating, Phase I Clinical Trial to Determine the Safety of a Single Dose of PAT-SM6 Monoclonal Antibody in Patients with Recurrent In-Transit Cutaneous Melanoma.
Phase of Trial: Phase I
Latest Information Update: 08 Jun 2016
At a glance
- Drugs PAT SM6 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Patrys
- 11 Jun 2013 Results have been published in Melanoma Research, and the trial met its primary safety endpoint, according to a Patrys media release.
- 20 Mar 2012 Final results published in a Patrys media release.
- 09 Feb 2012 Status changed from recruiting to completed, according to a Patrys media release.